TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00708656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalazine (Asacol®)
Description: 800 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalazine (Asacol®)
Description: 800 mg tablets
Study: NCT02103478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 Dose Escalation
Description: Oral investigational product and approved IV decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 Dose Confirmation
Description: Randomization cross over design for courses 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 Fixed-Dose Combination
Description: Fixed-dose investigational product
Study: NCT04993339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OOC
Description: The OOC will be mixed with autologous 5cc of platelet rich plasma (PRP), and then injected using a syringe into both tibia and femoral tunnels
Study: NCT03074721

Intervention type: DEVICE
Group type: OTHER
Intervention: PCI Suite Software
Description: PCI with PCI Suite Software

Intervention type: OTHER
Group type: OTHER
Intervention: conventional PCI
Description: conventional PCI without PCI Software
Study: NCT00125827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine (oral formulation)
Description: Cohorts of 3 patients each were to receive oral clofarabine administered daily for 5 days followed by 23 days of rest (1 cycle) and repeated every 28 days depending on toxicity and response. The starting dose of clofarabine was to be 1 mg/m2/day with subsequent dose escalation to occur in increments of 50% for the first 5 dose levels (1.5, 2.25, 3.5, and 5.0 mg/m2/day) and in increments of 25% thereafter until the MTD/RP2D was determined.
Study: NCT05029167

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive PaO2
Description: Patients are randomized to a PaO2 target of 9-10 kPa (open-label).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive PaO2
Description: Patients are randomized to a PaO2 target of 9-10 kPa (open-label).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal MAP
Description: The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal MAP
Description: The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal PaO2
Description: Patients are randomized to a PaO2 target of 13-14 kPa (open-label).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal PaO2
Description: Patients are randomized to a PaO2 target of 13-14 kPa (open-label).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal MAP
Description: The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal MAP
Description: The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
Study: NCT02008955

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysine intake provided as a milkshake
Description: There are 7 different lysine test levels ranging from 10 to 80 mg of lysine per kilogram body weight per day (10 - 80 mg/kg/d)
Study: NCT03842202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive gradually increasing doses of semaglutide (subcutaneous \[s.c.\], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive once weekly injections of semaglutide matched placebo.
Study: NCT04206072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0316 Capsule
Description: The initial dose of D-0316 is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD until disease progression or meet the discontinuation criteria. A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were confirmed T790M mutation positive may have the option to continuously receive D-0316.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib Hydrochloride Tablets
Description: Icotinib (125 mg three times daily, orally), treatment should continue until disease progression or meet the withdrawal criteria. A cycle of treatment is defined as 21 days of three times daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Icotinib arm and confirmed T790M mutation positive have the option to receive D-0316 (crossover to active D-0316).
Study: NCT03949764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (Epclusa®)
Description: The protocol is intended to follow best practices/standard of care for the treatment of HCV, with additional allowances for the investigators to apply rigorous scientific practices for the research aspects of the study. While the treatment of HCV is fairly straightforward, less is known about treating active drug users and RNA-positive individuals in rural areas. We propose eight visits, including intake, four treatment-related visits, and three visits to determine re-infection (6- and 12-months post-SVR). Because determination of medication adherence and long-term reinfection rates are not part of standard clinical practice, the rural protocol developed at the conclusion of KeY Treat will be streamlined based on findings, consisting of five or fewer clinical contacts. The drug used for treatment is Epclusa®, a 12-week, once per day, pan-genotypic DAA with a favorable side effect profile. Vosevi® will also be available in cases where participants are non-responsive or are re-infected.
Study: NCT03165253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium Animalis Oral Product
Description: The synbiotic group will receive this product.

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin Oral Tablet
Description: 50mg/kg/day B.I.D.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Oral Tablet
Description: 50mg/kg/day B.I.D.

Intervention type: DRUG
Group type: OTHER
Intervention: Clarithromycin Oral Tablet
Description: 15 mg/kg/day B.I.D.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin Oral Tablet
Description: 15 mg/kg/day B.I.D.

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: 1 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 1 mg/kg/day
Study: NCT02134431

Intervention type: DEVICE
Intervention: flexible sigmoidoscopy or colonoscopy with biopsies
Description: Lower endoscopy with biopsies (specifically either colonoscopy or flexible sigmoidoscopy) in both HIV-positive subjects already on oral tenofovir , as well as HIV negative subjects. Biopsies will be taken to laboratory for quantification of HIV-1 and drug levels of tenofovir.

Intervention type: DEVICE
Intervention: flexible sigmoidoscopy or colonoscopy with biopsies
Description: Lower endoscopy with biopsies (specifically either colonoscopy or flexible sigmoidoscopy) in both HIV-positive subjects already on oral tenofovir , as well as HIV negative subjects. Biopsies will be taken to laboratory for quantification of HIV-1 and drug levels of tenofovir.
Study: NCT02289599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307
Study: NCT03536728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXT1501
Description: AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXT1501
Description: AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXT1501
Description: AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules
Study: NCT01540370

Intervention type: OTHER
Intervention: No Treatment
Description: No treatment
Study: NCT01412840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diclofenac and sterile water injections
Description: The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac and isotonic saline
Description: The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
Study: NCT02566759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.
Study: NCT02289599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307
Study: NCT02566759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Suspension
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Placebo
Description: TAK-831 placebo-matching oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Placebo
Description: TAK-831 placebo-matching oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Placebo
Description: TAK-831 placebo-matching oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Placebo
Description: TAK-831 placebo-matching oral suspension.
Study: NCT04839835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: waiting room enriched with music, paintings and artificial plants
Description: waiting room enriched with music, paintings and artificial plants
Study: NCT03862807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patisiran
Description: Patisiran was administered via IV infusion.
Study: NCT00558831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl Peroxide
Description: Benzoyl Peroxide 2.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl Peroxide
Description: Benzoyl Peroxide 2.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizing Lotion
Study: NCT01915485

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lu 177
Description: Patients will be submitted to 4 cycles of 177-Lu with 200mCi each
Study: NCT03840473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET
Description: The patient was in a supine position with the cervical spine in the opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were in a lengthened position.19 The moderate isometric contraction (approximately 75% of maximal) of the upper trapezius muscles was elicited for a period of 5 seconds followed by 3 seconds of relaxation while reaching the new barrier. The technique was repeated four times in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET
Description: The patient was in a supine position with the cervical spine in the opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were in a lengthened position.19 The moderate isometric contraction (approximately 75% of maximal) of the upper trapezius muscles was elicited for a period of 5 seconds followed by 3 seconds of relaxation while reaching the new barrier. The technique was repeated four times in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICT
Description: The patient lying in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position.18,22 The physiotherapist applied gradually increasing pressure to the MTrPs until the subject perceived the first noticeable pain. At that moment, the pressure was maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure was increased until the discomfort appeared again. This process was maintained for 90 seconds.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Intervention
Description: Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Intervention
Description: Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Intervention
Description: Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.
Study: NCT04189666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine Transdermal System [Exelon]
Description: compare the ability of the drug in preventing postoperative delirium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: compare the ability of the drug in preventing postoperative delirium
Study: NCT04051658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
Study: NCT04471766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Certified cloth face mask plus preventive information
Description: Provision of two face masks sewed locally following a certified model tested for FORCE in the laboratory per residents \> 10 years old

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive information
Description: Advice on how to prevent COVID-19 according to the government´ policy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preventive information
Description: Advice on how to prevent COVID-19 according to the government´ policy
Study: NCT01934062

Intervention type: PROCEDURE
Intervention: Surgery
Description: All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 \& 7/31/2013.~--------------------------------------------------------------------------------
Study: NCT04376073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh \<77 kg) po QD day1\~21, Anlotinib 12mg po QD day1\~14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg po QD day1\~14. Starting dose of anlotinib changed to 10mg from 2020-11-13.
Study: NCT03777800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body therapy
Description: Body therapy involving direct physical treatments, conversations, breathing exercises and relaxation in the sessions. Moreover, the participants are taught how to practice vipassana or awareness meditation every day at home.~The body therapist works directly with the muscle armour and the treatment sessions have focus on creating a safe environment and enabling cognitive realisation and awareness of symptoms.~Each participant is assigned a practitioner who acts as contact person and 'lifeline'. Furthermore, a coordinator is assigned in ManuVision who will also act as contact person when needed for the veterans. This provides peace of mind, trust, and ensures retention. The coordinator or the practitioner follows up on the veteran's progress prior to each session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard treatment
Study: NCT00903409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin + Lovaza® (omega-3-acid ethyl esters)
Description: Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) \[formerly known as Omacor\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin + Lovaza® (omega-3-acid ethyl esters)
Description: Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) \[formerly known as Omacor\]
Study: NCT02850783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 89Zr-nanocoll and Indocyanine Green
Study: NCT01124500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate via transdermal patch compared to placebo
Description: The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.